Secondary outcomes
Wexner constipation, anxiety, pain, mood disorder, depression
The baseline VAS scores of the two groups were similar, and there was no significant difference in VAS scores between the two groups at any time after the beginning. However, VAS scores in both groups showed a decreasing trend compared with baseline, which in the L‐TAMS group were significantly lower than the baseline level since day 14 (L‐TAMS group 5.83 vs. Placebo group 6.21, Comparison of mean daily VAS pain intensity scores between the L‐TAMS and placebo groups, shown as the mean ± SD. No obvious difference of VAS scores between the two groups was observed at any time point.VAS, visual analogue scaleThere was no significant difference in PHQ‐9 scores at any time point between the two groups and changes in PHQ‐9 scores compared with their respective baseline levels (Figure There was no significant difference in mood disorder symptoms (depression (A) or anxiety (B)) between the L‐TAMS and placebo groups; values are shown as the mean ± SD. PHQ‐9, patient health questionnaire‐9; GAD‐7, generalized anxiety disorder‐7Considering the difference in the mean baseline Wexner scores between the two groups (L‐TAMS group 20.14 vs. Placebo group 17.37, Comparison of adjusted Wexner constipation scores between the L‐TAMS and placebo groups after correction of baseline values by analysis of covariance. From day 7 to day 90, there was a significant score difference between the two groups. Values are shown as the mean ± SD (***: 